EUCTR2015-001702-33-HU进行中（未招募）1 期
A 24-week International, Multicenter, Randomized, Open-Label, Active-Controlled, Parallel Group, Phase 3b Trial with a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered with Dapagliflozin Compared to Insulin Glargine in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin with or without Sulfonylurea Therapy
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 598
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Males and females aged = 18 years old at the time of screening visit.
- •Subjects with T2DM with inadequate glycemic control, defined as a central laboratory HbA1c = 8 % and = 12 % obtained at the screening visit.
- •Subjects must be taking a stable dose of metformin = 1500 mg/day for at least 8 weeks prior to screening visit with or without a stable dose of SU of at least 50% maximal dose per local label for at least 8 weeks prior to screening visit. Subjects must not take any other antidiabetic therapy for more than 14 days (consecutive or not) during 12 weeks prior to screening.
- •BMI = 45.0 kg/m2 at the screening visit.
- •Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of hCG) at screening and within 24 hours prior to the start of study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 478
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 120
排除标准
- •Clinical diagnosis of Type 1 Diabetes.
- •History of diabetic ketoacidosis
- •History of unstable or rapidly progressing renal disease, hepatic insufficiency or current, acute or chronic pancreatitis.
- •Any of the following cardiovascular/vascular diseases within 3 months of enrollment visit: myocardial infarction (MI), coronary arterial bypass graft (CABG), percutaneous coronary intervention (PCI), valvular disease or repair, unstable angina or unstable congestive heart failure (CHF), transient ischemic attack (TIA), Class III or IV heart failure, known left ventricular ejection fraction of < 40%, or significant cerebrovascular disease.
- •Impairment of renal function (defined as creatinine clearance [CrCl] < 60 mL/min [estimated by Cockcroft-Gault] or serum creatinine [SCr] = 1.5 mg/dL in male subjects or = 1.4 mg/dL in female subjects).
- •Bladder cancer
- •Hematuria (confirmed by microscopy at screening) with no explanation as judged by the investigator up to randomization.
- •Other hematological or oncological diseases or conditions.
- •Participation in a commercial weight loss program or history of bariatric surgery.
- •Replacement or chronic systemic corticosteroid therapy.
- •Administration of any other investigational drug or participation in any interventional clinical study within (30) days prior to screening for this study.
研究者
相似试验
进行中（未招募）
1 期
A comparison of treatment with Saxagliptin and Dapagliflozin against Insulin Glargine in Type 2 Diabetes patients whose current treatment of Metformin with or without Sulfonylurea Therapy is not adequate.Type 2 diabetes mellitus and inadequate glycemic control on a stable dose of metforminMedDRA version: 19.1Level: LLTClassification code 10049746Term: Insulin-requiring type II diabetes mellitusSystem Organ Class: 100000004861MedDRA version: 19.1Level: LLTClassification code 10063624Term: Type II diabetes mellitus inadequate controlSystem Organ Class: 100000004861MedDRA version: 19.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2015-001702-33-DEAstraZeneca AB598
进行中（未招募）
1 期
A comparison of treatment with Saxagliptin and Dapagliflozin against Insulin Glargine in Type 2 Diabetes patients whose current treatment of Metformin with or without Sulfonylurea Therapy is not adequate.Type 2 diabetes mellitus and inadequate glycemic control on a stable dose of metforminMedDRA version: 19.0Level: LLTClassification code 10049746Term: Insulin-requiring type II diabetes mellitusSystem Organ Class: 100000004861MedDRA version: 19.0Level: LLTClassification code 10063624Term: Type II diabetes mellitus inadequate controlSystem Organ Class: 100000004861MedDRA version: 19.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2015-001702-33-DKAstraZeneca AB598
进行中（未招募）
1 期
A comparison of treatment with Saxagliptin and Dapagliflozin against Insulin Glargine in Type 2 Diabetes patients whose current treatment of Metformin with or without Sulfonylurea Therapy is not adequate.Type 2 diabetes mellitus and inadequate glycemic control on a stable dose of metforminMedDRA version: 18.1Level: LLTClassification code 10049746Term: Insulin-requiring type II diabetes mellitusSystem Organ Class: 100000004861MedDRA version: 18.1Level: LLTClassification code 10063624Term: Type II diabetes mellitus inadequate controlSystem Organ Class: 100000004861MedDRA version: 18.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2015-001702-33-ESAstraZeneca AB598
进行中（未招募）
1 期
A comparison of treatment with Saxagliptin and Dapagliflozin against Insulin Glargine in Type 2 Diabetes patients whose current treatment of Metformin with or without Sulfonylurea Therapy is not adequate.Type 2 diabetes mellitus and inadequate glycemic control on a stable dose of metforminMedDRA version: 20.0Level: LLTClassification code 10049746Term: Insulin-requiring type II diabetes mellitusSystem Organ Class: 100000064343MedDRA version: 20.0Level: LLTClassification code 10063624Term: Type II diabetes mellitus inadequate controlSystem Organ Class: 100000019249MedDRA version: 20.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000072461EUCTR2015-001702-33-CZAstraZeneca AB598
进行中（未招募）
1 期
A comparison of treatment with Saxagliptin and Dapagliflozin against Insulin Glargine in Type 2 Diabetes patients whose current treatment of Metformin with or without Sulfonylurea Therapy is not adequate.Type 2 diabetes mellitus and inadequate glycemic control on a stable dose of metforminMedDRA version: 19.0Level: LLTClassification code 10049746Term: Insulin-requiring type II diabetes mellitusSystem Organ Class: 100000004861MedDRA version: 19.0Level: LLTClassification code 10063624Term: Type II diabetes mellitus inadequate controlSystem Organ Class: 100000004861MedDRA version: 19.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2015-001702-33-SEAstraZeneca AB598